Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapy for HCV Primary Treatment Failure in Pakistan
NCT05248919Enrolling by invitation
- Sponsor
- Queen Mary University of London
- Start
- Jun 2023
- Primary completion
- Sep 2027
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of velpatasvir in hepatitis C (HCV) (3 arms), sponsored by Queen Mary University of London. Primary endpoint: Sustained Virological Response at 36 weeks. Started Jun 2023; status: enrolling by invitation.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05248919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248919.